Abstracts by keywords: public tender offers
From portfolio to active ingredient contracts – Are aspects of adequate supply taken into account?
Since 2003, health insurance companies have been able to conclude individual discount agreements with pharmaceutical manufacturers. Due to a change in the legal situation, since the beginning of 2009, drug discount contracts in the form of active ingredient contracts have had to be advertised across Europe if the turnover covered by this exceeds 193,000 euros. The change from freely negotiated so-called portfolio contracts to tenders has led to various problems in the reality of supply. This article examines the topic from different perspectives and provides information on how, with the involvement of all those involved, discount agreements can be integrated smoothly into the (standard) supply landscape.